Business Context and Reporting Period
Company: The Cigna Group
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2024
Business Overview: A global health company operating through two primary reportable segments: Evernorth Health Services (pharmacy and specialty care) and Cigna Healthcare (medical and coordinated solutions). The company also maintains run-off operations and corporate functions.
Key Financial Metrics
| Metric (in millions) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Total Revenues | $60,523 | $48,586 | $117,778 | $95,103 |
| Shareholders' Net Income | $1,548 | $1,460 | $1,271 | $2,727 |
| Diluted EPS | $5.45 | $4.92 | $4.43 | $9.15 |
| Operating Cash Flow (YTD) | $5,105 | $7,520 | $5,105 | $7,520 |
| Total Debt (Short + Long Term) | $31,892 | $30,930 | $31,892 | $30,930 |
| Cash and Equivalents | $6,788 | $7,822 | $6,788 | $7,822 |
Note: Debt figures include short-term debt of $1,717 million and long-term debt of $30,175 million as of June 30, 2024.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 25% in Q2 2024 and 24% YTD compared to 2023. This was driven primarily by a 33% increase in Pharmacy revenues due to higher claims volume from new clients (including Centene) and organic growth.
- Profitability Volatility: While Q2 Shareholders' Net Income increased 6% year-over-year, YTD Net Income decreased 53%. This significant YTD decline was primarily driven by a $1.8 billion impairment loss on equity securities (VillageMD) recognized in Q1 2024.
- Investment Losses: Net realized investment losses were $1,884 million YTD 2024 compared to a loss of $30 million YTD 2023, largely due to the aforementioned equity impairment and credit loss charges on debt securities.
- Customer Base: Total medical customers decreased 2% to 19.0 million, primarily reflecting a decline in Individual and Family Plans customers.
Guidance, Outlook, and Risks
- Strategic Divestiture: In January 2024, the Company entered an agreement to sell its Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, and related businesses to Health Care Service Corporation (HCSC) for approximately $3.3 billion in cash. The transaction is expected to close in Q1 2025. Proceeds are anticipated to be used primarily for share repurchases.
- Capital Allocation: The Company repurchased approximately $5.0 billion of common stock YTD 2024, including $3.2 billion via Accelerated Share Repurchase (ASR) agreements. Dividends were declared at $1.40 per share for Q2 and Q3 2024.
- Medicare Star Ratings: The Company estimates 69% of its Medicare Advantage customers will be in four-star or greater plans for 2025 bonus payments, up from 67% for 2024.
- Risks and Contingencies:
- Investment Portfolio: The portfolio remains in a net unrealized depreciation position due to rising interest rates. Management monitors credit quality, noting weak fundamentals in the office sector for commercial mortgage loans, though exposure is limited.
- Legal Proceedings: Ongoing litigation with Elevance Health regarding pharmacy benefit management pricing and service claims. While a settlement was reached on service claims, pricing claims remain on appeal.
- Regulatory Environment: Risks related to government-sponsored programs (Medicare), changes in drug pricing benchmarks, and potential impacts of inflation and interest rates.
Investor Verification Checklist
- Investment Impairment: Verify the details and future impact of the $1.8 billion VillageMD equity impairment recorded in Q1 2024.
- HCSC Transaction: Monitor the regulatory approval status and expected closing timeline (Q1 2025) for the $3.3 billion sale of Medicare businesses.
- Pharmacy Volume Sustainability: Assess the sustainability of the 33% revenue growth in the Evernorth segment driven by new client acquisitions.
- Debt Maturities: Review the schedule of long-term debt maturities and the Company's strategy for refinancing or repaying obligations in the current interest rate environment.
- Medical Cost Trends: Evaluate the Medical Care Ratio (MCR) trends in the Cigna Healthcare segment, which increased 110 basis points in Q2 2024.